文献速递心律失常

Amulet与Watchman FLX左心耳封堵术后3年临床结局比较:SWISS-APERO随机试验

3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

SWISS-APERO试验将221例高出血风险房颤患者随机分配至Amulet或Watchman/FLX组行左心耳封堵,比较3年心血管死亡、卒中、TIA或系统性栓塞复合终点。意向治疗分析显示Amulet组复合缺血终点数值更低但未达统计学显著性(18.2% vs 31.0%;HR 0.58;95%CI 0.33-1.03;P=0.06),而在As-treated和Per-protocol分析中差异显著。

要点

  • 3年复合缺血终点在Amulet组数值更低但意向治疗分析未达显著差异
  • As-treated和Per-protocol分析中Amulet组复合缺血终点显著低于Watchman组
  • 结果属假说生成性质,需进一步研究验证

核心结论

  • 左心耳封堵术后3年,Amulet与Watchman FLX组间缺血风险无显著差异。
  • Amulet组在As-treated和Per-protocol分析中复合缺血终点更低,属假说生成,需进一步研究。

研究设计与样本

  • 研究者发起的SWISS-APERO随机试验,8个中心,高出血风险房颤患者1:1随机分配至Amulet或Watchman/FLX。
  • 共221例患者随机,220例完成左心耳封堵,3例随机至Amulet者实际接受Watchman FLX。
  • 3年随访率:Amulet组96.4%,Watchman组97.3%。

主要发现

  • 意向治疗分析:复合缺血终点Amulet组18.2% vs Watchman组31.0%(HR 0.58;95%CI 0.33-1.03;P=0.06)。
  • As-treated分析:复合缺血终点Amulet组17.0% vs Watchman组31.1%(HR 0.53;95%CI 0.30-0.96;P=0.035)。
  • Per-protocol分析:复合缺血终点Amulet组16.2% vs Watchman组29.2%(HR 0.54;95%CI 0.29-1.00;P=0.049)。

临床怎么用

  • 在高出血风险房颤患者行左心耳封堵时,Amulet与Watchman FLX均为可选器械,3年缺血结局无显著差异。
  • Amulet组在As-treated和Per-protocol分析中复合缺血终点更低,但属假说生成,不能据此改变临床决策。

局限性

  • 3例随机至Amulet组患者实际接受Watchman FLX,可能影响意向治疗分析结果。
  • 研究结果为假说生成性质,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No study thus far has compared Amulet with Watchman FLX for clinical outcomes beyond 1 year after percutaneous left atrial appendage closure (LAAC). OBJECTIVES: The goal of this study was to compare Amulet and Watchman FLX in terms of 3-year clinical outcomes. METHODS: In the investigator-initiated SWISS-APERO (Comparison of Amplatzer Amulet and Watchman Device in Patients Undergoing Left Atrial Appendage Closure) trial, patients with atrial fibrillation and high bleeding risk undergoing LAAC were randomly assigned (1:1) to receive Amulet or Watchman/FLX across 8 centers. Study endpoint included the composite of cardiovascular death, stroke, transient ischemic attack, or systemic embolism at 3 years. Analyses were repeated in the as-treated (AT) and per-protocol (PP) populations. RESULTS: Of the 221 patients randomized to treatment, 220 completed LAAC and 3 patients randomized to receive the Amulet device received the Watchman FLX device. The follow-up rate at 3 years was 96.4% in the Amulet group and 97.3% in the Watchman group. The composite ischemic endpoint occurred numerically less frequently in the Amulet group compared with the Watchman group (18.2% vs 31.0%; HR: 0.58; 95% CI: 0.33-1.03; P = 0.06). In both the AT (17.0% vs 31.1%; HR: 0.53; 95% CI: 0.30-0.96; P = 0.035) and PP (16.2% vs 29.2%; HR: 0.54; 95% CI: 0.29-1.00; P = 0.049) populations, the composite ischemic endpoint was significantly lower in the Amulet group compared with the Watchman group. CONCLUSIONS: At 3 years after LAAC, there was no significant difference in the ischemic risk between the Amulet and the Watchman FLX groups. The lower occurrence of the ischemic composite endpoint observed in the Amulet group in both the AT and PP analyses is hypothesis generating and emphasizes the need for further studies. (Comparison of Amplatzer Amulet and Watchman Device in Patients Undergoing Left Atrial Appendage Closure [SWISS-APERO]; NCT03399851).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Galea, De Marco, Aminian, et al. 3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial. J Am Coll Cardiol. 2025. PMID: 40602941. doi:10.1016/j.jacc.2025.03.535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。